Tharimmune, Inc. | WebDisclosure

Basculer en Français

8300	Companies
115014	Keywords
55394	Articles
62493	Press releases

Home
Companies
Tharimmune, Inc.

PRESS RELEASE

published on 07/22/2024 at 14:30, 3 months 30 days ago

Tharimmune Appoints Prof. David Jones of Newcastle University to its Scientific Advisory Board
Tharimmune, Inc. appoints Prof. David Jones, an expert in autoimmune liver disease, to its Scientific Advisory Board. Prof. Jones brings valuable insights to advance lead drug candidate TH104 for PBC patients

Scientific Advisory Board TH104 Tharimmune David Jones Autoimmune Liver Disease
BRIEF

published on 07/17/2024 at 14:35, 4 months 4 days ago

Tharimmune Appoints Global Business Executive David H. Clarke as Key Strategic Advisor

Biotechnology Strategic Advisor Tharimmune David H. Clarke
BRIEF

published on 07/17/2024 at 14:35, 4 months 4 days ago

Tharimmune nomme David H. Clarke, directeur commercial mondial, au poste de conseiller stratégique clé

Biotechnologie Conseiller Stratégique Tharimmune David H.Clarke
PRESS RELEASE

published on 07/17/2024 at 14:30, 4 months 4 days ago

Tharimmune Appoints Global Business Executive David H. Clarke as Key Strategic Advisor
Tharimmune, Inc. appoints David H. Clarke as Strategic Advisor, bringing valuable experience to enhance company's leadership and growth in inflammation and immunology therapeutics

Biotechnology Appointment Tharimmune Inc. Inflammation David H. Clarke
BRIEF

published on 07/10/2024 at 14:35, 4 months 11 days ago

Tharimmune nomme Jules Haimovitz au poste de conseiller stratégique clé

Biotechnologie Conseiller Stratégique Tharimmune Jules Haimovitz Programme Phase 2
BRIEF

published on 07/10/2024 at 14:35, 4 months 11 days ago

Tharimmune Appoints Jules Haimovitz as Key Strategic Advisor

Biotechnology Strategic Advisor Tharimmune Jules Haimovitz Phase 2 Program
PRESS RELEASE

published on 07/10/2024 at 14:30, 4 months 11 days ago

Tharimmune Appoints Jules Haimovitz as Key Strategic Advisor
Tharimmune, Inc. appoints Jules Haimovitz as Strategic Advisor, leveraging his biotechnology leadership and experience. The move enhances Tharimmune's clinical programs and FDA Phase 2 progress

Biotechnology Tharimmune Inc. Clinical Programs Jules Haimovitz FDA Phase 2
BRIEF

published on 06/17/2024 at 14:05, 5 months 4 days ago

Tharimmune annonce une réunion positive de type C avec la FDA pour le programme de phase 2 du TH104

FDA TH104 Essai De Phase 2 Tharimmune CBP
BRIEF

published on 06/17/2024 at 14:05, 5 months 4 days ago

Tharimmune Announces Positive Type C Meeting with FDA for Phase 2 Program for TH104

FDA TH104 Phase 2 Trial Tharimmune PBC
PRESS RELEASE

published on 06/17/2024 at 14:00, 5 months 4 days ago

Tharimmune Announces Positive Type C Meeting with FDA for Phase 2 Program for TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis
Tharimmune, Inc. receives positive FDA Type C meeting feedback for TH104 Phase 2 program, targeting pruritus in PBC patients, plans 505(b)(2) pathway for approval

FDA Feedback Tharimmune Inc TH104 Phase 2 Pruritus PBC Patients

Accesswire

Published on 11/21/2024 at 15:30, 22 minutes ago

CLS Health Opens New Comprehensive Care Clinic in Sugar Creek
Published on 11/21/2024 at 15:05, 47 minutes ago

"The Not-So-Secret Lives of REAL 'Mormon' Wives" - the Eye-Opening New Book From Cedar Fort Publishing & Media - is Now Available for Purchase, Just in Time for Christmas
Published on 11/21/2024 at 15:00, 52 minutes ago

2-10 Home Buyers Warranty Makes Triumphant Entry Into Oklahoma Market
Published on 11/21/2024 at 15:00, 52 minutes ago

Sound Physicians’ ACO Achieves $22.9M Total Savings in 2023 Medicare Shared Savings Program
Published on 11/21/2024 at 15:00, 52 minutes ago

BlackBerry AtHoc "In Process" Finalization for FedRAMP High Authorization

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 15:41, 10 minutes ago

Edison issues report on Murray Income Trust (MUT)
Published on 11/21/2024 at 15:24, 28 minutes ago

Form 8.3 - The Vanguard Group, Inc.: International Paper Company
Published on 11/21/2024 at 15:23, 29 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Centamin plc
Published on 11/21/2024 at 15:22, 30 minutes ago

Form 8.3 - The Vanguard Group, Inc.: TI Fluid Systems plc
Published on 11/21/2024 at 15:20, 31 minutes ago

Form 8.3 - The Vanguard Group, Inc.: AngloGold Ashanti plc

Les Echos

Published on 11/21/2024 at 06:58, 8 hours 54 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 8 hours 54 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 8 hours 54 minutes ago

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 19 hours 44 minutes ago

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 20 hours 32 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

View all LES ECHOS COMFI WIRE